This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Pharmaceuticals Highlights 13 Abstracts At The 55th Annual Meeting Of The American Society Of Hematology (ASH), New Orleans, Louisiana, December 7-10, 2013

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 55th Annual Meeting of the American Society of Hematology (ASH), being held in New Orleans, Louisiana, from December 7-10, 2013.

For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference website at
The following are key ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use-related
abstracts being presented at the ASH meeting:
Abstract #       Type       Title       First Author       Date/Time
1839 Poster P53 Based Strategy for Protection of Su Saturday, Dec. 7
Bone Marrow from Y-90 Ibritumomab 5:30 PM-7:30 PM
                                Hall G
2923 Poster Comparing The Cost-Effectiveness Of Chen Sunday, Dec. 8,
Rituximab Maintenance (MR) and 6:30 PM-8:30 PM
Radioimmunotherapy (RIT) Consolidation
Therapy Following First-Line Hall E
Chemo/Immunochemotherapies For
                Follicular Lymphoma                
3039 Poster A Single Center Phase II Trial of Samaniego Sunday, Dec. 8,

6:30 PM-8:30 PM
Produces High Response Rates as First-
Line Therapy for Early Stage B Cell Hall G
Indolent Lymphoma, including Bulky
3350 Poster Outcomes Following Autologous Stem Cell Khouri Sunday, Dec. 8,
Transplantation (ASCT) In Patients 6:30 PM-8:30 PM
With Germinal Center B (GCB) and Non-
GCB Cell-Like Diffuse Large B Cell Hall G
Lymphomas (DLBCL) According To
Conditioning With BEAM-Rituximab
(Standard vs. High-Dose) Vs.
BEAM/Yttrium-90 Ibritumomab Tiuxetan
369 Oral A randomized phase II study comparing Lopez-Guillermo Monday, Dec 9,
consolidation with a single dose of 10:30 AM-12:00 PM

90Y ibritumomab tiuxetan (Zevalin®)
(Z) vs. maintenance with rituximab (R) La Nouvelle
for two years in patients with newly Ballroom AB
diagnosed follicular lymphoma (FL)
responding to the regimen R-CHOP.
Preliminary results at 36 months from
4384 Poster Radioimmunotherapy In Ferrero Monday, Dec. 9,
Relapsed/Refractory Mantle Cell 6:00 PM-8:00 PM
Lymphoma Patients: Final Results Of a
                European MCL Network Phase II Trial               Hall G
4404 Poster Yttrium-90-Ibritumomab tiuxetan Puvvada Monday, Dec. 9,
(Zevalin) radioimmunotherapy after 6:00 PM-8:00 PM
cytoreduction with ESHAP chemotherapy
in patients with relapsed Follicular Hall G
Non-Hodgkin’s Lymphoma (NHL): Interim
                Results of a phase II study                
The following are key FOLOTYN® (pralatrexate injection) related abstracts being presented at
the ASH meeting:
Abstract #       Type       Title       First Author       Location
3044       Poster       A Phase II Study of Cyclophosphamide,       Advani       Sunday, Dec. 8,
Etoposide, Vincristine and Prednisone 6:30 PM-8:30 PM
(CEOP) Alternating with Pralatrexate
(P) as Front Line Therapy for Patients Hall G
with Peripheral T-Cell Lymphoma
(PTCL): Preliminary Results from the
                T- Cell Consortium Trial                
4284 Poster Analysis Of Peripheral T-Cell Lymphoma Carson Monday, Dec. 9,
(PTCL) Subtype By Race and 6:00 PM-8:00 PM
Geography Using The Comprehensive
Oncology Measures For Peripheral T- Hall G
Cell Lymphoma Treatment (COMPLETE)
4430 Poster Pre-Clinical Analysis Of The Novel Mangone Monday, Dec. 9,
Antifolate Pralatrexate In Multiple 6:00 PM-8:00 PM
Myeloma Reveals Functional Biomarkers
                Correlated With Response               Hall G
The following are key Marqibo® (vinCRIStine sulfate LIPOSOME injection) related abstracts
being presented at the ASH conference:
Abstract #       Type       Title       First Author       Location
2676       Poster       High-Dose Vincristine Sulfate Liposome       Deitcher       Sunday, Dec. 8,
Injection (Marqibo(®)) Is Not 6:30 PM-8:30 PM
Associated With Clinically Meaningful
                Hematologic Toxicity               Hall E
3033 Poster Long Term Results of Vincristine Hagemeister Sunday, Dec. 8,
Sulfate Liposome Injection 6:30 PM-8:30 PM

(Marqibo ®, M) Substituted for Non-
Liposomal Vincristine in R-CHOP to Hall G
create R-CHMP in Patients with
Untreated Diffuse Large B-Cell
4355 Poster Vincristine Sulfate Liposome Injection Kaplan Monday, Dec. 9,

(Marqibo ®) and Rituximab for
6:00 PM-8:00 PM
Patients with Relapsed and Refractory
Diffuse Large B-Cell Lymphoma or Hall G
Mantle Cell Lymphoma in Need of
                Palliative Therapy                

About Non-Hodgkin's Lymphoma

According to the National Cancer Institute (, there are expected to be 69,740 new cases of non-Hodgkin's lymphoma diagnosed and approximately 19,020 deaths in the United States in 2013. Non-Hodgkin's lymphoma is defined as any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin's lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. These types can be divided into aggressive (fast-growing) and indolent or low grade (slow-growing) types, and they can be formed from either B-cells or T-cells. Prognosis and treatment depend on the stage and type of disease.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market four oncology drugs ─ FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights; and MARQIBO® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at


FOLOTYN, (pralatrexate injection), a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, INC. In September 2009, the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory PTCL. This indication is based on overall response rate. Clinical benefit, such as improvement in progression-free survival or overall survival, has not been demonstrated. FOLOTYN has been available to patients in the U.S. since October 2009. An updated analysis of data from PROPEL, the pivotal study of FOLOTYN in patients with relapsed or refractory PTCL, was published in the March 20, 2011 issue of the Journal of Clinical Oncology. FOLOTYN has patent protection through July 2022, based on a five-year patent term extension through the Hatch-Waxman Act.

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.73 -1.20%
FB $117.59 0.74%
GOOG $694.08 0.44%
TSLA $240.85 -2.80%
YHOO $36.66 0.19%


Chart of I:DJI
DOW 17,778.54 -52.22 -0.29%
S&P 500 2,063.56 -12.25 -0.59%
NASDAQ 4,771.9090 -33.3820 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs